Erasca/$ERAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Ticker
$ERAS
Sector
Primary listing
Employees
103
Headquarters
Website
Erasca Metrics
BasicAdvanced
$4.3bn
-
-$0.96
0.68
-
Price and volume
Market cap
$4.3bn
Beta
0.68
52-week high
$24.28
52-week low
$1.21
Average daily volume
4.7m
Financial strength
Current ratio
9.518
Quick ratio
9.267
Long term debt to equity
10.343
Total debt to equity
11.677
Profitability
EBITDA (TTM)
-130.678
Management effectiveness
Return on assets (TTM)
-17.92%
Return on equity (TTM)
-69.86%
Valuation
Price to book
11.04
Price to tangible book (TTM)
11.04
Price to free cash flow (TTM)
-16.094
Free cash flow yield (TTM)
-6.21%
Free cash flow per share (TTM)
-0.869
Growth
Earnings per share change (TTM)
62.41%
3-year earnings per share growth (CAGR)
-19.65%
What the Analysts think about Erasca
Analyst ratings (Buy, Hold, Sell) for Erasca stock.
Erasca Financial Performance
Revenues and expenses
Erasca Earnings Performance
Company profitability
Erasca News
AllArticlesVideos
Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Business Wire·15 minutes ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS
Newsfile Corp·1 hour ago
Deadline Approaching: Erasca, Inc. (ERAS) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Business Wire·23 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs